Lack of relationship between systemic exposure for the component drugs of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients

Journal of Clinical Oncology

Volumn 14, Issue 5, 1996, Pages 1581-1588

  Sandstrom M ^a   Freijs, A ^a   Larsson, R ^a   Nygren, P ^a   Fjallskog M L ^a   Bergh, J ^a   Karlsson, M O ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE; DRUG METABOLITE; EPIRUBICIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; PRIORITY JOURNAL;

EID: 0029958848     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.5.1581     Document Type: Article

References (27)

1. Harris JR, Morrow M, Bonadonna G: Cancer of the breast, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer Principles and Practice of Oncology (ed 4). Philadelphia, PA. Lippincott 1993, pp 1264-1332
2. Evans WE, Relling MV: Clinical pharmacokinetics-pharmacodynamics of anticancer drugs. Clin Pharmacokinet 16:327-336, 1989
3. Morris RG, Kotasek D, Paltridge G: Disposition of epirubicin and metabolites with repeated courses to cancer patients. Eur J Clin Pharmacol 40:481-487, 1991
4. Moore MJ, Erlichman C, Thiessen JJ, et al: Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer. Cancer Chemother Pharmacol 33:472-476, 1994
5. Paalzow L: Therapeutical drug monitoring of anticancer drugs, in Domellöf L (ed): Drug Delivery in Cancer Treatment III. Berlin, Germany, Springer-Verlag, 1990, pp 85-96
6. Johansson M, Bielenstein M: Determination of 4-hydroxycyclophosphamide in plasma, as 2,4-dinitrophenylhydrazone derivative of aldophosphamide, by liquid chromatography. J Chromatogr B 660:111-120, 1994
7. Koks CHW, Van der Kam HJ, Brouwers JRBJ: A simple high pressure liquid chromatographic method for the determination of fluorouracil to monitor patients on regional infusion for hepatic metastases. Pharm Weekbl Sci 12:154-157, 1990
8. Robert J: Extraction of antracyclines from biological fluids for HPLC evaluation. J Liq Chromatogr 3:1561-1572, 1980
9. Launay MC, Milano G, Iliadis A, et al: A limited sampling procedure for estimating Adriamycin pharmacokinetics in cancer patients. Br J Cancer 90:89-92, 1989
10. Israel M, Pegg WJ, Wilkinson PM, et al: Liquid chromatographic analysis of Adriamycin and metabolites in biological fluids. J Liq Chromatogr 1:795-809, 1978
11. Beal SL, Sheiner LB: NONMEM Users Guides. San Fransisco, CA, NONMEM Project Group, University of California, 1992
12. Whiting B, Kelman AW, Grevel J: Population pharmacokinetics. Theory and clinical application. Clin Pharmacokinet 11:387-401, 1986
13. Sheiner LB, Grasela TH Jr: An introduction to mixed effects modeling: Concepts, definitions, and justification. J Pharmacokinet Biopharm 19: 11S-24S, 1991 (suppl 3)
14. Karlsson MO, Sheiner LB: The importance of modeling interoccasion variability in population pharmacokinetic analyses. J Pharmacokinet Biopharm 21:735-750, 1993
15. Hall AG, Cattan AR: Drug resistance mechanisms in leukaemia. Baillieres Clin Haematol 4:655-681, 1991
16. Weiss RB: The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol 19:670-686, 1992
17. Robert J: Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs 45:20-30, 1993 (suppl 2)
18. Schalhorn A, Kühl M: Clinical pharmacokinetics of fluorouracil and folinic acid. Semin Oncol 19:82-92, 1992 (suppl 3)
19. Santini J, Milano G, Thyss A, et al: 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br J Cancer 59:287-290, 1989
20. Moore MJ: Clinical pharmacokinetics of cyclophosphamide. Clin pharmacokinet 20:194-208, 1991
21. Sladek NE, Doeden D, Powers JF, et al: Plasma concentrations of 4-hydroxycyclophosphamide and phosphoramide mustard in patients repeatedly given high doses of cyclophosphamide in preparation for bone marrow transplantation. Cancer Treat Rep 68:1247-1254, 1984
22. Schuler U, Ehninger G, Wagner T: Repeated high-dose cyclophosphamide administration in bone marrow transplantation: Exposure to activated metabolites. Cancer Chemother Pharmacol 20:248-252, 1987
23. Moore MJ, Hardy RW, Thiessen JJ, et al: Rapid development of enhanced clearance after high-dose cyclophosphamide. Clin Pharmacol Ther 44:622-628, 1988
24. Reilly JJ, Workman P: Normalisation of anti-cancer drug dosage using body weight and surface area - Is it worthwhile - A review of theoretical and practical considerations. Cancer Chemother Pharmacol 32:411-418, 1993
25. Wade JR, Kelman AW, Kerr DJ, et al: Variability in the pharmacokinetics of epirubicin: A population analysis. Cancer Chemother Pharmacol 29:391-395, 1992
26. Diasio RB and Harris BE: Clinical pharmacology of 5-fluorouracil. Clin Pharmacokinet 16:215-237, 1989
27. Focan C, Andrien JM, Closon MTh, et al: Dose-response relationship of epirubicin-based first-line chemotherapy for advanced breast cancer: A prospective randomized trial. J Clin Oncol 11:1253-1263, 1993